NEW YORK, NY / ACCESSWIRE / November 24, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Kura Oncology, Inc. ("Kura" or the "Company") (NASDAQ:KURA). Investors who purchased Kura shares are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/kura.
The investigation concerns whether Kura and certain of its officers and/or directors have violated federal securities laws.
On November 24, 2021, Kura "announced that the U.S. Food and Drug Administration (FDA) has placed the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML) on a partial clinical hold." The Company advised that "[t]he partial clinical hold was initiated following the Company's recent report to the FDA of a Grade 5 serious adverse event (patient death) potentially associated with differentiation syndrome, a known adverse event related to differentiating agents in the treatment of AML[,]" and that "[u]ntil the partial clinical hold is resolved, and the Company has more clarity regarding the impact on timing, Kura is suspending guidance on the completion of enrollment in the KOMET-001 Phase 1b study and determination of the recommended Phase 2 dose of KO-539." On this news, Kura's stock price fell sharply during intraday trading on November 24, 2021.
If you are aware of any facts relating to this investigation or purchased Kura shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/kura. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC